Arrowhead announced the FDA has granted Fast Track designation to ARO-APOC3 for reducing triglycerides in adult patients with familial chylomicronemia syndrome, or FCS. ARO-APOC3 was previously granted Orphan Drug designation by the FDA and the European Union. ARO-APOC3 is Arrowhead’s investigational RNAi therapeutic targeting apolipoprotein C-III, or APOC3, being developed as a treatment for patients with severe hypertriglyceridemia, or SHTG, mixed dyslipidemia, or MD, and FCS. FCS is a rare genetic disorder that causes severely elevated triglyceride levels, which can result in acute and potentially fatal pancreatitis. There are currently no FDA approved therapies to treat FCS.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on ARWR:
- Arrowhead announces interim results from AROC3-1001 trial
- Arrowhead gets full rights to ARO-PNPLA3 to treat patients with NASH
- Arrowhead price target lowered to $55 from $59 at B. Riley
- 3 Stocks to Buy Today, 2/8/2023, According to Top Analysts
- Arrowhead price target lowered to $77 from $83 at RBC Capital